Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 4/20 | 0.49 |
| ▸ | HTR2C | P28335 | 3/20 | 0.49 |
| ▸ | HTR2B | P41595 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232364 | 1.00 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4 | |
| SCHEMBL23830675 | 1.00 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4 | |
| SCHEMBL30422913 | 0.91 | CHRNB2 (0.57) | SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4 | |
| SCHEMBL23745914 | 0.91 | CHRNB2 (0.57) | SLC6A2SLC6A4SLC6A3CHRNB2CHRNA4 | |
| SCHEMBL254980 | 0.90 | HRH1 (0.62) | SLC6A2SLC6A4SLC6A3HRH1HTR1A | |
| Hydrochloric Acid SCHEMBL3472570 | 0.89 | HRH1 (0.61) | SLC6A2SLC6A4SLC6A3HRH1HTR1A | |
| Hydrochloric Acid SCHEMBL29981033 | 0.89 | HRH1 (0.61) | SLC6A2SLC6A4SLC6A3HRH1HTR1A | |
| Hydrochloric Acid SCHEMBL23411157 | 0.87 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3HRH1HTR1A | |
| SCHEMBL1741795 | 0.86 | SLC6A4 (0.61) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL30164340 | 0.86 | SLC6A4 (0.61) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| WO-2012076063-A1 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | SLC6A2 5/4885SLC6A4 15/4885SLC6A3 21/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | SLC6A2 5/4885SLC6A4 15/4885SLC6A3 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.